Results 81 to 90 of about 158,388 (335)

Induction and maintenance of remission in acute leukemia [PDF]

Cancer, 1973
A total of 227 patients—124 with acute lymphoblastic leukemia (ALL) and 103 with acute myeloblastic leukemia (AML)—have been studied in order to evaluate the therapeutic effectiveness of vincristine, daunorubicin, and prednisone for induction followed by consolidation courses every 6 months with these drugs and either 6-mercaptopurine and methotrexate (
Guillermo Vilaseca, Santiago Pavlovsky, Alfredo Pavlovsky, Alberto Andino Pavlovsky, Jorge A. Peñalver, Luis J. Bergna, Argimiro Suarez, Mariana Eppinger-Helft, Federico Sackmann Muriel   +8 more
openaire   +2 more sources

Observational Study of Tocilizumab in Children With Febrile Infection‐Related Epilepsy Syndrome

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to assess the efficacy and safety of using tocilizumab in children with febrile infection‐related epilepsy syndrome (FIRES) and explore tocilizumab‐related changes in interleukin (IL)‐6 levels. Methods Patients with FIRES admitted to the Intensive Care Unit (ICU) of Beijing Children's Hospital were retrospectively ...
Yushan He, Jie Wu, Chaonan Fan, Zheng Li, Jun Liu, Kechun Li, Quan Wang, Suyun Qian   +7 more
wiley   +1 more source

Rituximab in glomerular diseases: a case series and narrative review

Brazilian Journal of Nephrology, 2021
Introduction: The use of Rituximab (RTX) in glomerular diseases (GD) has increased in the past years, although it is still only used in a small fraction of patients.
Inês Duarte, João Oliveira, Cristina Outerelo, Iolanda Godinho, Marta Pereira, Paulo Fernandes, Sofia Jorge, Joana Gameiro   +7 more
doaj   +2 more sources

Certolizumab pegol for induction of remission in Crohn's disease

Cochrane Database of Systematic Reviews, 2017
Crohn's disease (CD) is a chronic inflammatory disease of the gastrointestinal tract, and immune response modulation is the main treatment strategy to induce remission in active CD. Certolizumab pegol (CZP) is a tumor necrosis factor-alfa (TNF-α) inhibitor which regulates impaired immune response.The primary objectives were to evaluate the efficacy and
Yasushi Tsujimoto, Minoru Matsuura, Toshi A. Furukawa, Ryuhei So, Norio Watanabe, Shinichiro Shinzaki, Taku Kobayashi, Shinji Okabayashi, Katsuyoshi Matsuoka, Yuki Kataoka, Hajime Yamazaki   +10 more
openaire   +5 more sources

High‐Efficacy Treatment in Neuromyelitis Optica Specturm Disorder Patients With Seropositive AQP4 Antibodies—A Real‐World Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To compare the effectiveness of high‐efficacy treatments (HET) and low‐efficacy treatments (LET) in NMOSD patients with anti‐aquaporin‐4 antibodies (AQP4‐ab). Methods In this multi‐center study, we analyzed 183 AQP4‐ab seropositive NMOSD patients who received immunosuppressive treatments (IST).
Xiang Li, Binbin Xue, Jia Li, Dewei Xie, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Xu Zhang, Junhui Xia, Jie Lin   +10 more
wiley   +1 more source

Complete Remission of Acute Myeloid Leukemia in Induction and Consolidation Chemotherapy without Bone Marrow Transplantation: Lessons Learned from Good Presentation Case

Majalah Kedokteran Bandung, 2019
Acute myeloid leukemia (AML) is a clinically morphologically and genetically heterogeneous disease with variable responses to therapy. The majority of the patients eventually relapse and succumb to the disease.
Tuti Sri Hastuti, Rachmat Sumantri, Indra Wijaya   +2 more
doaj   +1 more source

Collection and composition of autologous peripheral blood stem cells graft in patients with acute myeloid leukemia: influence on hematopoietic recovery and outcome [Skupljanje i sastav transplantata autolognih krvotvornih matičnih stanica periferne krvi u bolesnika s akutnom mijeloičnom leukemijom: utjecaj na hematološki oporavak i ishod] [PDF]

, 2010
Hematopoietic stem cell (HSC) transplantation is a standard approach in the treatment of hematological malignant diseases. For the last 15 years the main source of cells for trasplantation have been peripheral blood stem cells (PBSC).
Batinić, Drago, Bojanić, Ines, Dubravčić, Klara, Dušak, Vesna, Golubić-Ćepulić, Branka, Labar, Boris, Mazić, Sanja, Mrsić, Mirando, Nemet, Damir, Raos, Mirela, Sertić, Dubravka, Serventi-Seiwerth, Ranka   +11 more
core  

Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia [PDF]

, 2004
We previously demonstrated prolonged, profound CD4+ T-lymphopenia in rheumatoid arthritis (RA) patients following lymphocyte-depleting therapy. Poor reconstitution could result either from reduced de novo T-cell production through the thymus or from poor
Bingham, S.J., Brown, A.K., Buch, M., Douglas, S.H., Emery, P., Fearon, U., Field, S.L., Isaacs, J.D., Lawson, C.A., Ma, D., Maltby, S.L., Markham, A.F., Masurel, A., McGonagle, D., Moore, J., Morgan, A.W., Papadaki, H.A., Patel, P., Ponchel, F., Protheroe, A., Quinn, M., Short, K., Snowden, J., Straszynski, L., van Laar, J.M., Veale, D.J., Verburg, R.J.   +26 more
core   +2 more sources

Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The choice of the first disease modifying treatment (DMT) in multiple sclerosis (MS) is a topic of great interest, and whether high‐efficacy DMTs should be the first choice remains debated. We compared treatment outcomes (no evidence of disease activity [NEDA] and its components) between treatment‐naïve relapsing–remitting MS (RRMS ...
Sarmad Al‐Araji, Marcello Moccia, Alessia Bianchi, Charmaine Yam, Weaam Hamed, Suraya Mohamud, Alan J. Thompson, Frederik Barkhof, Ahmed T. Toosy, Olga Ciccarelli   +9 more
wiley   +1 more source

Azathioprine-Induced Peripheral T Cell Apoptosis And Drug Response In Patients With Crohn’s Disease [PDF]

, 2011
Background and Aim: the long time interval for a trial of thioupurine therapy and the potential side effects in spite of the proven efficacy, do not encourage their use as early therapeutic option in Crohn’s Disease (CD).
Cossu, Andrea
core